Pre-made Envafolimab benchmark antibody ( Single Domain Variable Fragment;H, anti-CD274/PD-L1 therapeutic antibody, Anti-B7-H/B7H1/PDCD1L1/PDCD1LG1 Antibody) for drug discovery and mechanism of action (MOA) research

Pre-made Envafolimab benchmark antibody (Single Domain Variable Fragment;H, anti-CD274/PD-L1 therapeutic antibody, Anti-B7-H/B7H1/PDCD1L1/PDCD1LG1 Antibody) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Envafolimab is a novel, single-domain PD-L1 antibody that is administered by subcutaneous injection without the need for an adjuvant.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-ab-188-1mg	1mg	Inquiry
GMP-Bios-ab-188-10mg	10mg	Inquiry
GMP-Bios-ab-188-100mg	100mg	Inquiry
GMP-Bios-ab-188-xmg	≥100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Envafolimab biosimilar, Single Domain Variable Fragment;H, Anti-CD274/PD-L1 Antibody: Anti-B7-H/B7H1/PD-L1/PDCD1L1/PDCD1LG1/PDL1/hPD-L1 therapeutic antibody
INN Name	Envafolimab
Target	CD274
Format	Single Domain Variable Fragment;H
Derivation
Species Reactivity	Human
CH1 Isotype	IgG1
VD LC	na
Highest_Clin_Trial (Jan '20)	Preregistration
Est. Status	Active
100% SI Structure	None
99% SI Structure	None
95-98% SI Structure	None
Year Proposed	2018
Year Recommended	2019
Companies	Alphamab;3D Medicines;Sun Yat-Sen University
Conditions Approved	na
Conditions Active	Biliary cancer;Breast cancer;Solid tumours;Gastric cancer;Gastrointestinal cancer;Hepatitis B;Malignant fibrous histiocytoma;Soft tissue sarcoma
Conditions Discontinued	na
Development Tech	na